Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies. Our valuation framework helps you find stocks with the right balance of growth and value characteristics.
This analysis covers April 30, 2026 comments from CNBC Mad Money host Jim Cramer endorsing Johnson & Johnson (JNJ) as the preferred pharmaceutical sector holding for retail investors, in response to a caller query about rotating out of Novo Nordisk (NVO) into Organon & Co. (OGN). Cramer cited capped
Johnson & Johnson (JNJ) - Tapped as Defensive Large-Cap Healthcare Pick Amid Peer Rotation Recommendations - Asset Sale
JNJ - Stock Analysis
4575 Comments
1210 Likes
1
Josmary
Experienced Member
2 hours ago
Free US stock ESG scoring and sustainability analysis for responsible investing considerations. We evaluate environmental, social, and governance factors that increasingly impact long-term company performance.
👍 108
Reply
2
Lakeishia
Consistent User
5 hours ago
Investor sentiment remains broadly positive, supported by steady participation across multiple sectors. The market is experiencing a temporary consolidation phase, which is normal following recent strong gains. Technical patterns indicate that key support levels are well-maintained, reducing downside risk and suggesting a measured continuation of the current trend.
👍 281
Reply
3
Arden
Active Contributor
1 day ago
Market sentiment remains constructive for now.
👍 157
Reply
4
Vidharth
Returning User
1 day ago
I nodded while reading this, no idea why.
👍 222
Reply
5
Mistee
Insight Reader
2 days ago
Truly a benchmark for others.
👍 188
Reply
© 2026 Market Analysis. All data is for informational purposes only.